Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iterative-process highly-effective human diploid rabies vaccine
- Development stage
- Unknown
- Lead developer
- AIM Vaccine Co.
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
The iterative-process highly-effective human diploid rabies vaccine is an advanced, upgraded version of traditional human diploid rabies vaccines. Developed by AIM Vaccine, this vaccine is characterized by its significantly improved product quality, safety, and higher potency compared to first-generation human diploid rabies vaccines and Vero cell rabies vaccines. It addresses and overcomes technical challenges such as low virus titer and yield encountered in conventional production processes. The vaccine functions by inducing a robust immune response, specifically the production of high levels of protective antibodies, against the rabies virus. Its primary indication is for the prevention of rabies, a disease known for its nearly 100% fatality rate. This upgraded vaccine also offers flexible administration schedules, including five-needle, simple four-needle, or 2-1-1 four-needle approaches.
- Other names
- high-potency human diploid rabies vaccineiterative upgraded human diploid rabies vaccine
02
Targets
RABV-G (Rabies virus glycoprotein)
Beyond the preview
Go deeper on iterative-process highly-effective human diploid rabies vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iterative-process highly-effective human diploid rabies vaccine.